Similar articles

• Sirolimus to replace calcineurin inhibitors? Too early yet.

  Cravedi P, Ruggenenti P, Remuzzi G. Cravedi P, et al. Lancet. 2009 Apr 11;373(9671):1235-6. doi: 10.1016/S0140-6736(09)60709-1. Lancet. 2009. PMID: 19362662 Review. No abstract available.
• No recurrence of Kaposi's sarcoma in a case of renal retransplantation under a calcineurin inhibitor free immunosuppressive regimen: first report.

  Segoloni GP, Giraudi R, Messina M, Rossetti M, Biancone L, Leonardi G, Piccoli GB, Magnano A, Gai M. Segoloni GP, et al. Transpl Int. 2007 Apr;20(4):395-6. doi: 10.1111/j.1432-2277.2006.00435.x. Transpl Int. 2007. PMID: 17326783 No abstract available.
• Sirolimus for Kaposi's sarcoma in renal-transplant recipients.

  Stallone G, Schena A, Infante B, Di Paolo S, Loverre A, Maggio G, Ranieri E, Gesualdo L, Schena FP, Grandaliano G. Stallone G, et al. N Engl J Med. 2005 Mar 31;352(13):1317-23. doi: 10.1056/NEJMoa042831. N Engl J Med. 2005. PMID: 15800227 Clinical Trial.
• A novel immunosuppressive agent, sirolimus, in the treatment of Kaposi's sarcoma in a renal transplant recipient.

  Yilmaz R, Akoglu H, Kirkpantur A, Kilickap S, Arici M, Altun B, Aki T, Erdem Y, Yasavul U, Turgan C. Yilmaz R, et al. Ren Fail. 2007;29(1):103-5. doi: 10.1080/08860220601039528. Ren Fail. 2007. PMID: 17365918
• Calcineurin inhibitor-sparing regimens in solid organ transplantation: focus on improving renal function and nephrotoxicity.

  Flechner SM, Kobashigawa J, Klintmalm G. Flechner SM, et al. Clin Transplant. 2008 Jan-Feb;22(1):1-15. doi: 10.1111/j.1399-0012.2007.00739.x. Clin Transplant. 2008. PMID: 18217899 Review.